Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$41.71 USD

41.71
3,332,742

+0.28 (0.68%)

Updated Aug 23, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

PTC Therapeutics (PTCT) Halts Huntington's Disease Study in US

by Zacks Equity Research

The FDA requests additional data to allow PTC Therapeutics (PTCT) to continue enrollment in its phase II PIVOT-HD study evaluating PTC518 for treating Huntington's disease in the United States. Stock down.

Roche (RHHBY) Q3 Revenues Dip on Lower COVID-19-Related Sales

by Zacks Equity Research

Roche's (RHHBY) performance in the third quarter was pretty ho-hum as COVID-19-related sales continue to decline.

Will Ayvakit Aid Blueprint Medicines (BPMC) Amid Rivalry?

by Zacks Equity Research

Blueprint Medicines (BPMC) expects its lead drug, Ayvakit, which is approved to treat rare cancer and other rare diseases, to generate incremental sales and combat stiff competition.

Will Seagen's (SGEN) Portfolio of Drugs Help Combat Rivalry?

by Zacks Equity Research

Seagen (SGEN) expects its portfolio of marketed drugs, which are approved for various cancer indications, to generate incremental sales and combat stiff competition.

Will Loss of REGEN-COV Sales Hurt Regeneron (REGN) in 2022?

by Zacks Equity Research

Regeneron's (REGN) top line is affected by negligible sales from REGEN-COV while lead drug Eylea faces stiff competition.

Can Biogen (BIIB) Navigate Multiple Challenges & Grow Again?

by Zacks Equity Research

Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, we are hopeful that potential new product launches such as lecanemab, zuranolone and additional biosimilars can help revive growth.

Sarepta (SRPT) Seeks FDA Nod for DMD Gene Therapy Candidate

by Zacks Equity Research

If approved, Sarepta's (SRPT) SRP-9001 will be the first gene therapy for DMD indication in the United States. The company seeks approval for gene therapy under the accelerated pathway.

NVS vs. RHHBY: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

NVS vs. RHHBY: Which Stock Is the Better Value Option?

Ekta Bagri headshot

LLY & PRTA in Spotlight on BIIB-Eisai's AD Drug Data

by Ekta Bagri

The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well.

Biogen's (BIIB) Lecanemab Meets Goal in Alzheimer's Study

by Zacks Equity Research

Biogen (BIIB) and Eisai's Clarity AD study showed that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of clinical decline on the CDR-SB scale by 27% compared to placebo.

Seagen (SGEN) Inks Deal With LAVA Therapeutics for LAVA-1223

by Zacks Equity Research

Seagen (SGEN) signs an exclusive agreement with LAVA Therapeutics to develop and commercialize the latter's preclinical asset, LAVA-1223, targeting EGFR-expressing solid tumors.

Novartis (NVS) to Focus on US Markets Backed by 8 Key Drugs

by Zacks Equity Research

Novartis (NVS) unveils a new focused strategy with the spotlight on the US markets driven by eight key brands that are expected to have a multi-billion dollar peak sales potential.

Kinjel Shah headshot

Pharma Stock Roundup: EU Nod to AZN & RHHBY Drugs, FDA Updates for LLY & MRK

by Kinjel Shah

Roche's (RHHBY) eye drug, Vabysmo and AstraZeneca's (AZN) asthma drug Tezspire get approval in Europe. The FDA approves expanded use of Lilly's (LLY) cancer drug, Retevmo.

Novartis (NVS) to Appeal to Supreme Court for Gilenya Patent

by Zacks Equity Research

Novartis (NVS) is looking to defend its patents for the multiple sclerosis drug Gilenya and file a petition in the Supreme Court after an unfavorable ruling in the federal court.

Seagen's (SGEN) Tukysa Gets FDA Priority Review for New Indication

by Zacks Equity Research

FDA grants priority review to Seagen's (SGEN) sNDA for Tukysa in combination with trastuzumab for previously treated HER2-positive metastatic colorectal cancer. A decision is due on Jan 19, 2023.

Roche's (RHHBY) Vabysmo Gets Approval for nAMD & DME in Europe

by Zacks Equity Research

The European Commission approves Roche's (RHHBY) Vabysmo for treating neovascular or wet age-related macular degeneration and visual impairment due to diabetic macular edema.

Sarepta (SRPT) Stock Up 76.8% in Three Months: Here's Why

by Zacks Equity Research

Sarepta Therapeutics (SRPT) is progressing with the development of its pipeline, which focuses on treating DMD. It expects to initiate a BLA filing for its DMD gene therapy by year-end

Regeneron (REGN) Up on Higher Dose Eye Drug Studies Success

by Zacks Equity Research

Regeneron (REGN) stock jumps as aflibercept 8 mg with 12- and 16-week dosing regimens in patients with DME and wAMD meet primary goals.

Amgen (AMGN) Outperforms Industry Year to Date: What's Next?

by Zacks Equity Research

Amgen's (AMGN) key drugs like Prolia, Repatha and Xgeva are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.

    Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe

    by Zacks Equity Research

    Puma Biotech (PBYI) has only one marketed product in its portfolio, Nerlynx, for HER-2 positive breast cancer patients. It continues to evaluate Nerlynx in other types of cancer and indications.

    Novartis (NVS) Plans to Spin Off Generics Business Sandoz

    by Zacks Equity Research

    Novartis (NVS) is set to spin off Sandoz into a new publicly traded standalone company to focus better on its core pharmaceutical business.

    AbbVie (ABBV) Outperforms Industry This Year So Far: Here's Why

    by Zacks Equity Research

    AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.

    Roche's (RHHBY) sBLA For Polivy Combo Accepted by FDA

    by Zacks Equity Research

    Roche's (RHHBY) sBLA seeking approval for the use of Polivy in combination with R-CHP for previously untreated diffuse large B-cell lymphoma in adults has been accepted in the United States.

    Roche (RHHBY) Influenza Drug Gets FDA Nod for Children

    by Zacks Equity Research

    Roche (RHHBY) obtains FDA approval for expanded indication of influenza drug Xofluza.

    Halozyme (HALO) Q2 Earnings and Sales Beat, Ups '22 Outlook

    by Zacks Equity Research

    Halozyme's (HALO) second-quarter earnings and sales beat estimates. Following the completion of the acquisition of Antares Pharma, the company raises its financial guidance for 2022.